Op vrijdag heeft BMO Capital Markets het koersdoel voor de aandelen van Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) verhoogd van $520 naar $545, terwijl het Outperform-advies werd gehandhaafd. H ...
A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...
VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...
The NICE-Vertex saga continued this month with Vertex’s CEO Jeffrey Leiden hinting at ‘new ideas’ to bring cystic fibrosis drug Orkambi to UK patients. Leiden said that he is to meet with ...
Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England.
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback